Browse the evidence

Current bariatric surgery guidelines (BMI >= 35, or 30-34.9 with comorbidities) may need re-evaluation due to the efficacy of pharmacotherapy.

If your BMI is between 30 and 40, you may not need surgery. Ask your doctor about GLP-1 medications, which are now effective enough to potentially replace surgery for many patients.

Women experience a significantly lower efficacy-to-tolerability ratio than men when treated with GLP-1 receptor agonists, characterized by disproportionately higher rates of persistent nausea and vomiting relative to weight loss.

If you are a woman taking a GLP-1 medication like semaglutide or tirzepatide, you are statistically more likely to experience nausea and vomiting than a man taking the same drug, even if you lose more weight. This is not a failure of willpower but a biological difference in how your body processes the drug, likely driven by estrogen levels. Discussing this with your provider may lead to strategies like slower dose escalation or phase-specific dosing to manage side effects.

Once-weekly insulin icodec provides glycemic control similar to once-daily insulin glargine with comparable hypoglycemia rates, potentially improving patient acceptability through reduced injection frequency.

If daily injections are burdensome, ask your doctor about once-weekly insulin icodec. It works as well as daily insulin for blood sugar control and has similar side effects, but offers the convenience of fewer injections.

Changes in soluble LDL receptor (sLDLR) levels are strongly associated with changes in atherogenic lipoprotein phenotype (ALP) markers, including triglycerides, VLDL, and small LDL particles, independent of diet type (low-carbohydrate vs. low-fat) and BMI change.

This research highlights that soluble LDL receptor (sLDLR) levels track closely with atherogenic lipid profiles (high triglycerides, small LDL) during weight loss, regardless of whether you choose a low-carb or low-fat diet. While sLDLR itself is not a standard clinical target, its association with these markers suggests that individuals with high sLDLR may have a specific metabolic phenotype (atherogenic dyslipidemia) that requires careful monitoring of lipid health during weight loss interventions.

Tirzepatide treatment significantly reduces food cravings and preferences for energy-dense foods (high fat, high sugar, fast food fats) in people with obesity, independent of caloric restriction.

If you struggle with intense cravings for high-fat or high-sugar foods, tirzepatide can help reduce these urges. This isn't just about willpower; the medication physiologically lowers the 'pull' of these foods, making it easier to stick to a healthy diet.

Tirzepatide specifically reduces cravings for fast-food fats (e.g., pizza, hamburgers) more than other high-fat foods (e.g., sausage, fried fish).

Tirzepatide may be particularly effective at reducing cravings for specific fast-food items like pizza and burgers compared to other high-fat foods.

GLP-1 receptor agonist (GLP-1RA) treatment in obese individuals causes a modest absolute decrease in skeletal muscle mass, but preserves or improves relative muscle mass and strength, resulting in maintained or enhanced physical performance.

If you are taking GLP-1 medications for weight loss, expect a small, normal amount of muscle loss alongside your fat loss. This is not pathological wasting; your muscles are actually working better relative to your new body weight. Focus on maintaining strength through activity, as your mobility and endurance may actually improve.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists are indicated for patients with type 2 diabetes who are inadequately controlled on oral antihyperglycemic drugs (OADs) with an HbA1c less than 10% and within 2% of their glycemic goal, or for those already on basal insulin who remain above goal.

If you are taking oral diabetes medications but your blood sugar is still too high (HbA1c less than 10% and within 2% of your target), or if you are already on basal insulin but your levels are still above goal, ask your doctor about a fixed-ratio combination (FRC). These are single injections that combine a long-acting insulin with a GLP-1 medication. They are designed to lower blood sugar effectively, minimize weight gain, and reduce the number of injections you need to manage compared to traditional basal-bolus therapy.

For patients with Type 2 Diabetes requiring basal insulin, a glycated hemoglobin (HbA1c) goal of less than 7% is appropriate, whereas a goal of less than 6.5% is less likely to be appropriate due to increased risks of hypoglycemia and weight gain.

If you are on basal insulin, aim for an HbA1c of less than 7%. Trying to get it below 6.5% when you are on insulin can increase your risk of dangerous low blood sugar and weight gain without providing significant additional long-term benefits. Your doctor should adjust your goal based on your specific health situation, but <7% is generally the safe target for insulin users.

Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.

Orforglipron not only helps with weight loss but also significantly improves heart health markers. It lowers bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). These improvements occur alongside weight loss and contribute to a lower risk of cardiovascular disease, making it a comprehensive treatment for obesity-related metabolic risks.

Delaying the onset of type 2 diabetes by two years in individuals with obesity is associated with a 3.7-year increase in median life expectancy and reduced long-term mortality, primarily driven by lower cardiovascular mortality.

For individuals with obesity, preventing or delaying the onset of type 2 diabetes is a critical lever for extending life expectancy. This study suggests that even a modest two-year delay in developing diabetes can add nearly four years to your life, largely by protecting your heart. Focus on metabolic health markers (like blood sugar and insulin sensitivity) as aggressively as you focus on weight, as the timing of diabetes onset directly impacts how long you live.

Treatment with extended-release naltrexone/bupropion (NB) produces weight loss that is disproportionately derived from fat mass rather than lean mass compared to placebo, resulting in a favorable shift in the lean-to-fat mass ratio.

If you are using naltrexone/bupropion for weight loss, the medication helps you lose more fat and preserve more muscle than dieting alone. This is beneficial for long-term metabolic health. Ensure you are following a caloric deficit and staying active as instructed.

Consuming 50g of isomaltulose (ISO) as a preload before a mixed meal significantly enhances the secretion of gut hormones GLP-1, GIP, and PYY compared to sucrose (SAC), with a particularly pronounced effect on PYY levels in both healthy individuals and those with Type 2 Diabetes.

If you want to boost your gut hormones (GLP-1, PYY) which help regulate appetite and insulin, try eating 50g of isomaltulose (often found in products like Palatinose) about one hour before your main meal. This specific timing and dose triggers a much stronger hormonal response than regular table sugar (sucrose), especially regarding PYY, which is linked to satiety. Note that this did not significantly lower blood glucose in the subsequent meal in this study, so it is a tool for hormonal modulation, not necessarily glycemic control.

Dual and tri-agonists targeting GLP-1, GIP, and Glucagon receptors provide superior metabolic homeostasis and cardiovascular benefits compared to mono-agonists by leveraging cooperative hormonal signaling.

Current GLP-1 treatments are effective, but newer dual and triple hormone therapies (targeting GLP-1, GIP, and Glucagon receptors) offer broader metabolic and cardiovascular benefits. These are available as weekly or daily injections, and in some cases, oral formulations, addressing the burden of daily dosing.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce major adverse cardiovascular events (MACE), with benefits potentially driven by anti-atherogenic or plaque-stabilization properties, particularly in secondary prevention.

If you have Type 2 Diabetes and heart disease, injectable GLP-1 medications like liraglutide or semaglutide have been shown to reduce the risk of heart attack, stroke, and cardiovascular death. These benefits appear to come from protecting blood vessels (anti-atherogenic effects). Oral alternatives like DPP-4 inhibitors do not offer this specific heart protection.

Monogenic obesity caused by leptin deficiency can be effectively treated with recombinant leptin therapy, restoring normal appetite regulation.

This intervention is not for the general population. It applies only to a tiny fraction of individuals with confirmed monogenic leptin deficiency. Standard weight loss strategies remain the primary approach for >99% of cases.

Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.

Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

Higher postprandial endogenous GLP-1 release is positively correlated with hepatic and peripheral insulin sensitivity in individuals with class II/III obesity without diabetes, and this association persists one year after Roux-en-Y gastric bypass (RYGB).

For individuals with obesity, higher natural GLP-1 responses to meals are linked to better insulin sensitivity. While Roux-en-Y gastric bypass significantly amplifies this GLP-1 response, leading to improved metabolic health, the study suggests that the magnitude of this hormonal response is a key indicator of metabolic status. Non-surgical strategies that might support healthy incretin responses (though not explicitly detailed in this paper) could be beneficial, but the data strongly links the specific postprandial GLP-1 profile to insulin sensitivity.

Shifting nutrient absorption to the distal small intestine (ileum) significantly increases post-prandial GLP-1 and PYY secretion, improving glucose control and contributing to weight loss, as seen in bariatric surgery and with certain enzyme inhibitors.

Bariatric surgery works partly by forcing food to be digested further down the intestine, which triggers a strong hormone release (GLP-1/PYY) that helps control blood sugar and appetite. Some diabetes medications (like acarbose) mimic this by slowing digestion. This suggests that how and where food is absorbed matters as much as what is eaten.

GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.

For T2DM patients with heart or kidney risks, GLP-1 receptor agonists are a top choice. They help lower blood sugar, promote significant weight loss by reducing visceral fat, and protect the heart and kidneys. Discuss options like weekly injections or oral formulations with your doctor.